Shares of BioSyent Inc. (CVE:RX - Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$11.02 and traded as low as C$10.99. BioSyent shares last traded at C$11.30, with a volume of 30,477 shares.
BioSyent Stock Performance
The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. The stock has a fifty day moving average price of C$11.02 and a 200 day moving average price of C$10.22. The firm has a market cap of C$130.39 million, a price-to-earnings ratio of 18.83 and a beta of 0.93.
BioSyent (CVE:RX - Get Free Report) last released its earnings results on Monday, August 26th. The company reported C$0.13 earnings per share for the quarter, hitting analysts' consensus estimates of C$0.13. The business had revenue of C$8.95 million for the quarter, compared to the consensus estimate of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. As a group, analysts predict that BioSyent Inc. will post 0.6944444 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company's stock in a transaction dated Friday, September 20th. The stock was sold at an average price of C$10.95, for a total value of C$25,404.00. Insiders own 33.65% of the company's stock.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Articles
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
